Off the Beaten Track丨Klone 4.0--An AI-empowered Cell Line Development Platform Makes Debut

Created on:2020-09-16 10:37


September 16th,2020 Press Release

Off the Beaten Track丨Klone 4.0--An AI-empowered Cell Line Development Platform Makes Debut

[2020/9/2, Dongguan]The three-day MedInvest International Conference was officially concluded at 9 P.M. (Hongkong Time) on September 10, 2020. Michael Chen, CEO of Great Bay Bio, was invited to attend the conference and publicly demonstrated Klone4.0 platform for the first time, echoing the call of the integration of artificial intelligence and bio-pharmaceutical industries. During the "one-to-one" session, GBB’s technology caught eyes of world-class institutions, pharmaceutical innovators and industry investors who in turn expressed their interests to work in partnership with Great Bay Bio and looked forward to the official launch of Klone4.0 platform on October 15.

MedInvest International Conference boasts a professional platform which is tailored to boost communications among participants from big data, digital health and other fields. GBB’s Klone4.0 platform serves as a pioneer to use artificial intelligence technology to develop cell lines, and rapidly analyzes and locates high-yielding cells via cell image recognition and AI algorithm. Moreover, it enjoys obvious market competitive edges and broad investment space as it is capable of selecting high-yield monoclonal cells through unique single-cell selection technology.

Klone4.0 platform not only gets off the beaten track of traditional drug research and development and reducing much intensive labors, but also greatly improves the possibility of success in screening process. It features fast, cost-effective, high yield rate and zero risk, which upgrades the working process and drives cell line development toward high-tech era.

"The MedInvest International Conference offers a “one-on-one” session where many of the world's leading institutions, drug innovators and industry investors are also in," Chen says. In the process of business negotiation, Klone4.0 platform has caught eyes of many peer companies and investment institutions due to its obvious advantages including "AI-empowered", "time and effort saving", "high quality", to name but a few. This is the icing on the cake for the official launch of our Klone 4.0 platform on October 15."


About Great Bay Bio 


Headquartered in Hong Kong, Great Bay Bio (GBB) is a high-tech enterprise developing biologics with AI technologies. Since its foundation, it has been committed to biotech and biologics development. It has founded Dongguan Taili Biotech Co., Ltd. and Guangzhou Taili Biomedical Technology Co., Ltd. Investing more than RMB 300 million, the company has successfully established the independent and integrated technology platform for drug R&D and large-scale preparation. Through customized CMC packaging services, it has successfully helped several products reach NDA stage, some of which are national class I new drugs.

GBB positions itself as a Contract Development and Manufacturing Organization (CDMO), applying AI technology to CMC (Chemistry, Manufacturing, Control) platform for drug development, which targets the drawbacks of drug development including long timeline and high costs, and solves them with the AI+CMC model. Based on massive datum obtained from conventional biologics development, CMC platform can build models and conduct AI analyses. Integrating AI and biotechnology, it can overcome hurdles in biologics development and greatly reduce the time and costs so as to provide much cheaper, efficient and high-quality drug development service for the clients, and also bring much economical drug to the society.

GBB has been recognized as the Patent Incubation Company, Patent Pilot Company, National High-tech Company, Dongguan New Research Institution, Guangdong Top Ten Foreign R&D Center, Guangdong R&D Center of Genetic Engineering Medicine and Engineering, and Guangdong Doctoral Workstation. Since 2006, it has undertaken a number of government projects. More than RMB 20 million has been received from the government to support its provincial and national projects, such as Guangdong-Hong Kong Key Breakthrough Project and National Major New Drug Projects.

The CMC platform has an area of over 3100 m2 and a whole set of advanced biopharmaceutical R&D equipment. The key equipment has been purchased from world-renowned manufacturers such as Sartorius, Bio-Rad, GE Healthcare, and Waters. The pilot workshop is designed strictly in accordance with cGMP requirements, mainly at the C level and some even at the A level.



For more details, please

Contact for

Contact for media and investment:

Home    News    Off the Beaten Track丨Klone 4.0--An AI-empowered Cell Line Development Platform Makes Debut